secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-124067
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reduces office space by 46,278 sq ft, extends lease for remaining space through 2030
--------------------------------------------------------------------------------

- Reduces leased premises by 46,278 rentable square feet (from 98,502 to 52,224) effective Sept 30, 2025.
- Term for remaining 52,224 sq ft extended five years through Sept 30, 2030, with annual rent escalation.
- Annual base rent for remaining space starts at $35.75/sq ft ($1.87M) and rises to $39.75/sq ft ($2.08M) by year 5.
- Landlord provides $2,219,520 tenant improvement allowance ($42.50/sq ft) for work in the retained premises.
- Tenant surrenders vacated portion on Sept 30, 2025, without required removal of certain initial alterations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017024124067/0000950170-24-124067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017024124067/kpti-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer